MKSI Stock Analysis: MKS Instruments | NASDAQ
Scientific & Technical Instruments | NASDAQ, USA | Market Cap: 21.931m USD | 12M Return: 236.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 544M
EPS Trend: 81.1%
Qual. Beats: 1
Rev. Trend: 43.1%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MKS Inc. supplies foundational technology solutions to semiconductor manufacturing, electronics and packaging, and specialty industrial markets, operating through three segments: Vacuum Solutions (VSD), Photonics Solutions (PSD), and Material Solutions (MSD). The VSD segment delivers pressure, flow, gas delivery, and gas analysis technologies; PSD offers lasers, photonics, optics, and precision motion control; and MSD provides surface modification, plating, and finishing technologies for chemistry, equipment, and high-technology applications. The company sells through direct sales, independent distributors, sales representatives, and online product catalogs, serving customers primarily in the United States, China, South Korea, Japan, Taiwan, and Singapore.
The firm is classified within the Semiconductor Materials & Equipment sub-industry, a sector that supplies critical subsystems, components, and consumables integrated into wafer fabrication and packaging lines operated by semiconductor manufacturers and OEMs. Originally incorporated in 1961 and headquartered in Andover, Massachusetts, the company was renamed MKS Inc. in May 2025, having previously operated as MKS Instruments, Inc.
- Semiconductor equipment demand rebound lifts Vacuum Solutions revenue
- Atotech integration progresses; MSD margin expansion remains key catalyst
- China revenue exposure heightens geopolitical risk amid export controls
| Net Income: 327.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.68 > 1.0 |
| NWC/Revenue: 6.24% < 20% (prev 45.03%; Δ -38.79% < -1%) |
| CFO/TA 0.06 > 3% & CFO 557.0m > Net Income 327.0m |
| Net Debt (3.97b) to EBITDA (898.0m): 4.42 < 3 |
| Current Ratio: 1.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.1m) vs 12m ago 5.02% < -2% |
| Gross Margin: 43.61% > 18% (prev 47.52%; Δ -3.91% > 0.5%) |
| Asset Turnover: 47.12% > 50% (prev 42.70%; Δ 4.42% > 0%) |
| Interest Coverage Ratio: 2.72 > 6 (EBIT TTM 554.0m / Interest Expense TTM 204.0m) |
| A: 0.03 (Total Current Assets 2.54b - Total Current Liabilities 2.29b) / Total Assets 8.73b |
| B: 0.09 (Retained Earnings 778.0m / Total Assets 8.73b) |
| C: 0.06 (EBIT TTM 554.0m / Avg Total Assets 8.64b) |
| D: 0.48 (Book Value of Equity 2.81b / Total Liabilities 5.92b) |
| Altman-Z'' = 1.41 = BB |
| DSRI: 1.09 (Receivables 775.0m/639.0m, Revenue 4.07b/3.65b) |
| GMI: 1.09 (GM 47.52% / 43.61%) |
| AQI: 0.98 (AQ_t 0.59 / AQ_t-1 0.60) |
| SGI: 1.11 (Revenue 4.07b / 3.65b) |
| TATA: -0.03 (NI 327.0m - CFO 557.0m) / TA 8.73b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of July 22, 2026, the stock is trading at USD 345.44 with a total of 1,106,303 shares traded. Over the past week, the price has changed by -3.62%, over one month by -17.86%, over three months by +26.27% and over the past year by +236.07%.
Current recommended Stop Loss: 310.80 (which is 10% or 1.3 ATR below the current price).
MKS Instruments has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy MKSI.
- StrongBuy: 7
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 406.9 | 17.8% |
P/E Trailing = 68.0692
P/E Forward = 10.3627
P/S = 5.3845
P/B = 7.8018
P/EG = 1.3236
Revenue TTM = 4.07b USD
EBIT TTM = 554.0m USD
EBITDA TTM = 898.0m USD
Long Term Debt = 2.65b USD (from longTermDebt, last quarter)
Short Term Debt = 1.40b USD (from shortTermDebt, last quarter)
Debt = 4.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 244.0m
Net Debt = 3.97b USD (calculated: Debt 4.54b - CCE 569.0m)
Enterprise Value = 25.9b USD (21.9b + Debt 4.54b - CCE 569.0m)
Interest Coverage Ratio = 2.72 (Ebit TTM 554.0m / Interest Expense TTM 204.0m)
EV/FCF = 64.58x (Enterprise Value 25.9b / FCF TTM 401.0m)
FCF Yield = 1.55% (FCF TTM 401.0m / Enterprise Value 25.9b)
FCF Margin = 9.85% (FCF TTM 401.0m / Revenue TTM 4.07b)
Net Margin = 8.03% (Net Income TTM 327.0m / Revenue TTM 4.07b)
Gross Margin = 43.61% ((Revenue TTM 4.07b - Cost of Revenue TTM 2.30b) / Revenue TTM)
Gross Margin QoQ = 41.19% (prev 40.46%)
Tobins Q-Ratio = 2.97 (Enterprise Value 25.9b / Total Assets 8.73b)
Interest Expense / Debt = 4.50% (Interest Expense 204.0m / Debt 4.54b)
Taxrate = 5.76% (20.0m / 347.0m)
NOPAT = 522.1m (EBIT 554.0m * (1 - 5.76%))
Current Ratio = 1.11 (Total Current Assets 2.54b / Total Current Liabilities 2.29b)
Debt / Equity = 1.61 (Debt 4.54b / totalStockholderEquity, last quarter 2.81b)
Debt / EBITDA = 4.42 (Net Debt 3.97b / EBITDA 898.0m)
Debt / FCF = 9.89 (Net Debt 3.97b / FCF TTM 401.0m)
Total Stockholder Equity = 2.67b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.78% (Net Income 327.0m / Total Assets 8.73b)
RoE = 12.24% (Net Income TTM 327.0m / Total Stockholder Equity 2.67b)
RoCE = 10.41% (EBIT 554.0m / Capital Employed (Equity 2.67b + L.T.Debt 2.65b))
RoIC = 6.84% (NOPAT 522.1m / Invested Capital 7.63b)
WACC = 13.99% (E(21.9b)/V(26.5b) * Re(16.01%) + D(4.54b)/V(26.5b) * Rd(4.50%) * (1-Tc(0.06)))
Discount Rate = 16.01% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 64.24 | Cagr: 2.61%
[DCF] Terminal Value 56.06% ; FCFF base≈421.0m ; Y1≈383.3m ; Y5≈333.8m
[DCF] Fair Price = N/A (negative equity: EV 2.76b - Net Debt 3.97b = -1.21b; debt exceeds intrinsic value)
EPS Correlation: 81.07 | EPS CAGR: 20.01% | SUE: 1.54 | # QB: 1
Revenue Correlation: 43.12 | Revenue CAGR: 2.05% | SUE: 2.67 | # QB: 1
EPS current Quarter (2026-06-30): EPS=2.96 | Chg30d=+0.20% | Revisions=+80% | Analysts=13
EPS next Quarter (2026-09-30): EPS=3.17 | Chg30d=+0.48% | Revisions=+79% | Analysts=13
EPS current Year (2026-12-31): EPS=11.74 | Chg30d=+0.38% | Revisions=+25% | GrowthEPS=+49.0% | GrowthRev=+22.3%
EPS next Year (2027-12-31): EPS=15.22 | Chg30d=+1.85% | Revisions=+25% | GrowthEPS=+29.6% | GrowthRev=+15.6%
[Analyst] Revisions Ratio: +89% (up=25, down=0)